Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
782 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05463796 | InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer | recruiting | — | 5,000 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07227584 | ALL Backbone in AYAs | recruiting | Phase 2 | 67 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| 'ADVANCE' (A Pilot Trial) |
| active not recruiting |
| Phase 1 |
| 41 |
| Dana-Farber Cancer InstituteOTHER |
| 1 |
| Aug 13, 2026 |
| clinicaltrials |
| NCT00936858 | RAD001 for Patients With Radioiodine Refractory Thyroid Cancer | completed | Phase 2 | 50 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT02657551 | A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer | completed | Phase 2 | 17 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT04608487 | Axi-cel in CNS Lymphoma | active not recruiting | Phase 1 | 18 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT03392246 | A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer | active not recruiting | Phase 2 | 25 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07426484 | Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy | recruiting | Phase 4 | 80 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06026111 | Preliminary Efficacy of Different Exercise Training During Immunotherapy in Patients With Lung Cancer: The ENHANCE Trial(ENHANCE) | recruiting | N/A | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07482384 | Supporting Health Including Endocrine Treatment for Long Duration(SHIELD) | recruiting | N/A | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT02670525 | Matched Targeted Therapy For High-Risk Leukemias and Myelodysplastic Syndrome | active not recruiting | N/A | 338 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT03316573 | Pembrolizumab in Neoplasms or Lymphomas | suspended | Phase 2 | 18 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT05721248 | STOP-HER2: Stopping Trastuzumab in HER2+ MBC | active not recruiting | Phase 2 | 82 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06439693 | The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer | recruiting | Phase 2 | 72 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07412041 | Precise Exercise Regimen for Cancer Care (PERCC): A Pilot Study(PERCC) | recruiting | N/A | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT05080166 | UPLYFT For Lymphoma Survivors | completed | N/A | 74 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT06736548 | Sleep Treatment Education Program for Cancer Survivors: STEP-Together | enrolling by invitation | N/A | 100 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT03689595 | Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE) | enrolling by invitation | — | 30,000 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT00400946 | 05-001: Treatment of Acute Lymphoblastic Leukemia in Children | completed | Phase 3 | 800 | Dana-Farber Cancer InstituteOTHER | 2 | Jul 30, 2026 | clinicaltrials |
| NCT04290546 | CIML NK Cell in Head & Neck Cancer | completed | Phase 1 | 11 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT05765500 | RecoverPC: Relugolix vs GnRH Agonist in Quality of Life | recruiting | Phase 2 | 110 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT04323774 | Intervention For Adolescents and Young Adults (AYAs) With Cancer Risk Syndromes(AYA-RISE) | active not recruiting | N/A | 115 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT05327465 | Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy | recruiting | N/A | 62 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT01574274 | SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma | active not recruiting | Phase 2 | 240 | Dana-Farber Cancer InstituteOTHER | 2 | Jul 28, 2026 | clinicaltrials |
| NCT02912572 | Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer | active not recruiting | Phase 2 | 106 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07732140 | Listen Aphasia Pilot Study(LISTEN) | not yet recruiting | N/A | 80 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT03417739 | A Phase II Study of BVD-523 in Metastatic Uveal Melanoma | terminated | Phase 2 | 13 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT04045470 | A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma | recruiting | N/A | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT02876302 | Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer | completed | Phase 2 | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT02523040 | Lenalidomide for Adult Histiocyte Disorders | active not recruiting | Phase 2 | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT03333616 | Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors | active not recruiting | Phase 2 | 100 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT04917796 | The Effect of Electroacupuncture on Nerve Pain Caused by Chemotherapy (Chemotherapy-Induced Peripheral Neuropathy)(ACT) | active not recruiting | N/A | 255 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT02251548 | A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia(iFCR) | active not recruiting | Phase 2 | 85 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07714551 | Zanzalintinib in Unresectable and Progressive MPGGs | not yet recruiting | Phase 2 | 14 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT05535192 | TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients(THRIVE-65) | recruiting | N/A | 270 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06758102 | Dance Study for Post-surgical Pain in Breast Cancer Survivors | active not recruiting | N/A | 28 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07710131 | Neurocognitive Assessment CNSL and LGG | not yet recruiting | N/A | 36 | Dana-Farber Cancer InstituteOTHER | 0 | Jul 17, 2026 | clinicaltrials |
| NCT03020030 | Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents | active not recruiting | Phase 3 | 560 | Dana-Farber Cancer InstituteOTHER | 2 | Jul 16, 2026 | clinicaltrials |
| NCT03075527 | A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma | terminated | Phase 2 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03425331 | Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC | terminated | Phase 2 | 5 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03716739 | Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency | completed | Phase 2 | 136 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04968834 | Genomically Profiling, Collecting, Archiving and Distributing Hematologic Malignancy Specimens | recruiting | — | 300 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06117709 | Integrated Smartphone Technology to Alleviate Malignant Pain (I-STAMP) Testing | not yet recruiting | N/A | 73 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06469307 | Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)(DIVERSE) | recruiting | N/A | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06795139 | Pilot of a Trial Enrollment Diversity Dashboard(TEDD) | completed | N/A | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06716580 | EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations(EQUAL) | recruiting | N/A | 1,000 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT02474368 | Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck | active not recruiting | Phase 1 | 21 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT02648997 | An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma | active not recruiting | Phase 2 | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT04717050 | Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity | completed | N/A | 64 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT06722014 | Integrating Pain-CBT Into an mHealth Analgesic Support Intervention for Patients With Chronic Pain From Advanced Cancers | completed | N/A | 64 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 8, 2026 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials